PROCEPT BioRobotics Corporation is a surgical robotics company focused on developing, manufacturing, and selling advanced, image-guided robotic systems for minimally invasive urologic surgery. The company’s primary products are the AquaBeam Robotic System and the HYDROS Robotic System, which deliver Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH). Aquablation therapy combines real-time multi-dimensional imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation to remove prostate tissue. The company serves hospitals, ambulatory surgery centers, and distribution partners, with a significant presence in the United States and a growing global install base. PROCEPT BioRobotics began developing its proprietary AquaBeam Robotic System in 2009. The company’s clinical evidence includes nine clinical studies and over 150 peer-reviewed publications, supporting the efficacy and safety of its therapy compared to standard surgical interventions.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage procept-biorobotics.com
Sector Healthcare IR page ir.procept-biorobotics.com
Tags
surgical robotics, urology, benign prostatic hyperplasia, waterjet ablation, image-guided surgery, minimally invasive surgery, men's health, single-use devices, AquaBeam Robotic System, HYDROS Robotic System, Aquablation therapy
Press page —

Metrics

Valuation  
Market cap $ 1.132B
Market cap (USD) $ 1.132B
P/E -9.71
PEG —
P/BV 3.44
P/S 3.21
P/OCF -14.77
P/FCF -13.31
Dividend yield —
Turnover / mcap —
Returns  
ROE -24.9%
ROI -22.9%
ROIC -18.7%
Profit margin -31.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 15.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score -38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 308.054M 224.498M 136.191M 75.014M 34.473M 7.717M
Net profit -95.572M -91.413M -105.897M -87.154M -59.853M -53.019M
Free cash flow -58.341M -103.622M -133.209M -83.035M -57.926M -48.576M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 31.46 80.52 41.91 41.54 25.01 —
Price performance 12m -0.61 0.92 0.01 0.66 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 1.55M 4.46M 15.3M 48.4M 83.5M 83.5M
↳ YoY growth +188.2% +242.1% +216.8% +72.6% +0.0%
↳ 5y CAGR +122.0%
Borrowings, current (USD) — 4.55M 0.00 — — — —
Borrowings, non-current (USD) — 44.4M 50M 51.2M 51.3M 51.5M 51.6M
Lease liabilities (USD) — 5.8M 4.1M 26.1M 27.9M 28.8M 26.9M
Cash and deposits (USD) 42.7M 100M 304M 222M 257M 334M 287M
Right-of-use assets (USD) — 4.64M 3.28M 23.5M 20.2M 18.9M 17.5M
Net debt (borrowings + leases - cash) (USD) — -45.4M -250M -145M -178M -253M -208M
Cash flow detail
Operating cash flow (USD) — -48.3M -57.3M -80.4M -108M -99.2M -49M
Purchases of property, plant and equipment (USD) — -233,000 -592,000 -2.65M -25.2M -4.41M -9.36M
Change in receivables (cash effect) (USD) — -511,000 -2.91M -10.8M -33.1M -36M -898,000
Change in inventories (cash effect) (USD) — -3.11M -6.12M -15.3M -9.75M -17.2M -14.5M
Change in payables (cash effect) (USD) — -205,000 812,000 3.96M 5.79M -2.15M 6.65M
Interest paid (cash effect) (USD) — -3.97M -4.75M -4.29M -4.06M -3.97M -3.46M
Income taxes paid (cash effect) (USD) — — — — -90,000 -80,000 -118,000
Share-based compensation (USD) — 2.17M 3.8M 10.3M 19.1M 31.8M 47.6M
Operating cash flow before change in receivables (USD) — -47.8M -54.4M -69.6M -74.9M -63.3M -48.1M
Free cash flow (OCF - PPE - intangibles) (USD) — -48.6M -57.9M -83M -133M -104M -58.3M
Income detail
Research and development expense (USD) — 16.3M 19M 29M 48.4M 62.3M 71.3M
↳ 5y CAGR +34.4%
Total comprehensive income (USD) — -53M -59.9M -87.1M -106M -91.4M -95.6M
Comprehensive income to owners (USD) — -53M -59.9M -87.1M -106M -91.4M -95.6M
Provision for credit losses (USD) — — — — 0.00 840,000 219,000
Credit cost ratio (credit losses / average receivables) (%) — — — — 0.0% 1.3% 0.3%
Reported Nov 5, 2021 Mar 22, 2022 Mar 22, 2022 Feb 28, 2023 Feb 26, 2026 Feb 26, 2026 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

SAN JOSE, Calif., November 4, 2026 -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026.

“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan,” said Larry Wood, Chief Executive Officer. “Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027. We see significant opportunity and a clear path to achieving durable growth and profitability ahead.”

Wood continued, “This quarter, we continued expanding our installed base and drove strong utilization in HYDROS® accounts. We delivered approximately 18% revenue growth and 22% U.S.

Oct 12, 2026

|

PDF Version

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. In addition to its leadership in BPH treatment, the Company is pursuing clinical research initiatives in prostate cancer utilizing investigational applications of its robotic and AI-enabled technologies. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Media Contact: Pooja Rao,[email protected] Investor Contact: Marissa Bych,[email protected]

Procept Biorobotics

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social Media Cookies

Social Media Cookies

These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

On October 2, 2026, the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) approved (i) an increase in the size of the Board from nine members to ten members, (ii) appointed Dr. Michael Mack as a new member of the Board to fill the resulting vacancy, effective immediately.

Dr. Mack was classified as a Class II director, and his initial term will expire at the Company’s 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier death, resignation or removal. The Board has determined that Dr. Mack is an “independent director” as defined under the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and the listing requirements and rules of the Nasdaq stock market.

Dr. Mack is a cardiac surgeon who has practiced in Dallas, Texas since 1982 and is board-certified in internal medicine, general surgery and thoracic surgery. He currently serves as Chairman of the Board of the Baylor Scott & White Research Institute and Associate Academic Officer of Baylor Scott & White Health. Dr.

Prompts

PROCEPT BioRobotics Corporation (ticker PRCT), listed in United States.

ETFs Holding PROCEPT BioRobotics Corporation

ETF Weight in ETF Shares Market value As of
LGHT 0.59% 641 $ 14.474K Jun 30, 2026
FSCC 0.39% 67,565 $ 1.432M Aug 31, 2026
TMED 0.19% 1,951 $ 44.054K Jun 30, 2026
SCDS 0.09% 364 $ 8,655.92 Nov 17, 2026
AVSC 0.01% 9,528 $ 224.289K Nov 16, 2026
DFAS 0.00% 26,613 $ 625.672K Nov 12, 2026
DXUV 0.00% 2,882 $ 67.756K Nov 12, 2026
DFSU 0.00% 65 $ 1,528.15 Nov 12, 2026
DFAU 0.00% 345 $ 8,110.95 Nov 12, 2026
DFAC 0.00% 591 $ 13.894K Nov 12, 2026
DCOR 0.00% 273 $ 6,418.23 Nov 12, 2026
AVSU 0.00% 20 $ 470.80 Nov 16, 2026
NTRL short 0.00% -7,119 $ 0.00 Nov 16, 2026